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Background:  Dopamine  (DA)  is  involved  in systems  governing  motor  actions,  motivational  processes  and
cognitive  functions.  Preclinical  studies  have  shown  that  even  relatively  low  doses  of  d-amphetamine
(dAMPH)  (equivalent  to  doses  used  in  clinical  Practice)  can  lead  to DA  neurotoxicity  in rodents  and
non-human  primates  (Ricaurte  et  al.,  2005).
Methods: Therefore,  we  investigated  the  DAergic  function  in  eight  male  recreational  users  of  dAMPH  and
eight  male  healthy  controls  using  functional  magnetic  resonance  imaging  (fMRI).  We  compared  brain
activation  between  both  groups  during  a monetary  incentive  delay  task  (Knutson  et al.,  2001)  with  and
without  an  oral  methylphenidate  (MPH)  challenge.  All subjects  were  abstinent  for  at  least  2 weeks  during
the  baseline  scan.  The  second  scan  was  performed  on  the  same  day  1.5 h after  receiving  an  oral  dose  of
35  mg  MPH  (approximately  0.5  mg/kg)  when  peak  MPH  binding  was  assumed.
Results:  When  anticipating  reward,  dAMPH  users  showed  lower  striatal  activation  in  comparison  to  con-
trol  subjects.  In  addition,  MPH  induced  a reduction  in  the  striatal  activation  during  reward  anticipation
in  healthy  controls,  whereas  no such  effect  was  observed  in  dAMPH  users.
Conculsion: The  combination  of  these  ﬁndings  provides  further  evidence  for frontostriatal  DAergic  dys-
function  in  recreational  dAMPH  users  and  is  consistent  with  preclinical  data  suggesting  neurotoxic  effects
of  chronic  dAMPH  use.  The  ﬁndings  of this  explorative  study  could  have  important  implications  for
humans  in need  for treatment  with  dAMPH,  such  as patients  suffering  from  ADHD  and  therefore  this
 a  larstudy  needs  replication  in
. Introduction
Dopamine (DA) is involved in several key physiological systems
overning motor actions as well as motivational processes and cog-
itive functions. Subsequently, abnormalities of dopaminergic cells
ave been linked to both Parkinson-like motor deﬁcits, attenuated
eward processing, and impaired impulse control (Van den Heuvel
nd Pasterkamp, 2008; Stoy et al., 2011; Vaidya et al., 1998.
In  humans, DAergic dysfunction can occur as a conse-
uence of endogenous disease processes (e.g., Parkinson’s dis-
ase, schizophrenia and attention deﬁcit/hyperactivity disorder
 Supplementary  materials for this article can be found by accessing the online
ersion  of this paper at http://dx.doi.org/10.1016/j.drugalcdep.2012.10.010. Please
ee  Appendix A for more information.
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(ADHD)), resulting in alterations in frontostriatal DAergic signaling
(Van den Heuvel and Pasterkamp, 2008). DAergic dysfunction can
also be caused by exogenous inﬂuences on the brain, such as the use
of dextro-amphetamine (dAMPH) or methamphetamine. Preclin-
ical studies have shown that even relatively low doses of dAMPH
(equivalent to the doses used in clinical practice) can lead to stri-
atal DA neurotoxicity in rodents and non-human primates (Ricaurte
et al., 2005), as evidenced for instance by reductions in striatal DA
concentrations and DA transporter (DAT) binding sites. PET stud-
ies in dAMPH treated monkeys have shown reductions in striatal
[18F]ﬂuoro-l-dopa uptake in vervet monkeys (Melega et al., 1996,
1997). In line with this, in humans, a study by Reneman et al. (2002)
has shown that recreational dAMPH use is linked to lower striatal
DAT availability. Because the DAT is a structural component of the
DA-axon, loss in DAT has been used as a marker for DAergic damage
Open access under the Elsevier OA license.(Reneman et al., 2002). Because dAMPH is frequently prescribed in
the treatment of ADHD it is a drug that is relatively easy to obtain
for illicit purposes and in fact is misused by subjects both with and
without ADHD (Wilens et al., 2008). Therefore it is important to
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urther investigate DA dysfunction in recreational users of dAMPH.
ecreational users, i.e., subjects not being treated for substance
buse, tend to use less frequently and lower dosages than subjects
ith a substance use disorder. To the best of our knowledge, no
ther studies have yet investigated the DA system in recreational
sers of this drug.
Studies  in abstinent dAMPH users have demonstrated sustained
eﬁcits in several behavioral paradigms, including decision-making
Ersche et al., 2005), memory (Rapeli et al., 2005) and set-shifting
Ornstein et al., 2000). Although functional MRI  (fMRI) meas-
res changes in blood oxygenation rather than neurochemistry,
t has been suggested that striatal activation during anticipation
f reward as measured with fMRI might partially index DAergic
unction (Schultz, 2002). In addition, fMRI can give region-speciﬁc
eurovascular responses to a DAergic challenge (Knutson et al.,
004); Willson et al., 2004). In view of this, it is of interest to inves-
igate anticipation of reward in recreational users of dAMPH and
heir reaction to a DA challenge. The combination of a DA challenge
ith fMRI (pharmacological MRI; phMRI) enables a more direct
ssessment of DA functions, because brain activity during striatal
ctivation is investigated in addition to the modulating effect of a
A agent (Honey and Bullmore, 2004).
A drug that is well known to activate the DA system is
ethylphenidate (MPH), commonly used in the treatment of
DHD. MPH  acts by blocking the DAT, which prevents the reuptake
f DA by the presynaptic neuron and thus increases DA concen-
ration in the synaptic cleft. Oral MPH  challenges have been used
n fMRI investigations involving both healthy and ADHD popula-
ions (Shafritz et al., 2004; Bush et al., 2008; Schlosser et al., 2009;
ubia et al., 2009), but not dAMPH users. MPH  normalized brain
esponses in ADHD patients on inhibitory tasks (Vaidya et al., 1998;
iddle et al., 2011) as well as reward-related tasks (Wilkison et al.,
995; Rubia et al., 2009).
In  this study, we investigated DAergic function in recreational
sers of dAMPH and healthy controls using fMRI with and with-
ut a DA challenge to determine whether dAMPH use can be
inked to DAergic dysfunction in humans. We  set out to answer
he following questions: (1) Does striatal function differ between
ecreational dAMPH users and control subjects? (2) Does a DAer-
ic challenge modulate striatal function differently in recreational
AMPH users versus control subjects? To that purpose, we  inves-
igated the response to an oral MPH  challenge during a DAergic
ask: anticipation of reward using a monetary incentive delay task
Knutson et al., 2001). In view of the fact that anticipation of reward
s linked in a large part to striatal response systems, which may
e disrupted in dAMPH users, we hypothesized that recreational
AMPH use is associated with impaired anticipation of reward and
hat this abnormality is (partially) restored by increased extracel-
ular levels of DA following oral MPH.
. Methods
.1. Subjects
Subjects were recruited by posting advertisements around the
edical campus, on websites and in regional newspapers. A total
f eight male, recreational amphetamine users and eight male,
ealthy control subjects were recruited. Written informed con-
ent was obtained from all subjects. The eligibility criterion for the
AMPH group was previous use of dAMPH on more than 40 occa-
ions. This threshold was chosen based on the work of Reneman
t al. (2002) who found lower DAT binding in ecstasy users with
verage dAMPH use on more than 45 occasions. The eight con-
rol subjects were healthy subjects with no self-reported use of
mphetamines. Dependence 130 (2013) 52– 60 53
Subjects were asked to refrain from using caffeinated prod-
ucts on assessment days. Both controls and dAMPH users agreed
to abstain from all psychoactive drugs for at least two weeks
before scanning and therefore dAMPH dependence was reason
for exclusion. All subjects indicated being able to abstain without
external help during this two  week period and were asked to com-
ply with urine drug screening on the day they were scanned (with
an enzyme-multiplied immunoassay for amphetamines, cocaine,
cannabis, alcohol, opiates and benzodiazepines). Exclusion criteria
for all participants were: any neuropsychiatric diagnosis or his-
tory of brain disease or injury, use of medication with afﬁnity for
DA (e.g., MPH), a positive urine-screen for any DAergic drugs or
any contra-indication to MRI  such as metallic implants or claustro-
phobia. Subjects received a small ﬁnancial compensation for their
participation.
This study was approved by the medical ethics committee of the
Academic Medical Center Amsterdam.
2.2. Procedure
The tasks were presented in the same order for every subject;
ﬁrst a go–nogo task, then the reward task and then an emotional
face recognition task. Results of the go–nogo task and the face
recognition task will be reported elsewhere. To minimize learning
effects, a practice run for each task was  presented outside of the
scanner. After the ﬁrst scanning session, subjects received 35 mg
MPH (approximately 0.5 mg  per kg body weight) to be taken orally
with water. Subjects were then free to relax for 1.5 h until peek
plasma levels were expected (Swanson and Volkow, 2003) and then
re-entered the MRI  scanner for the second session that was  iden-
tical to the ﬁrst. MPH  was obtained from Sandoz B.V. (Weesp, the
Netherlands).
2.3. Imaging
All  MR  imaging was performed using a 3.0 T Philips MR  scan-
ner equipped with an SENSE 8-channel head coil and body coil
transmission (Philips Medical Systems, Best, The Netherlands). The
session protocol consisted of a high resolution 3D T1-weighted
anatomical scan for registration and segmentation purposes and
a fast single shot echo planar image (EPI) sequence for BOLD
analysis. For the BOLD acquisition imaging parameters were:
TR/TE 2300/30 ms;  FOV 220 mm  × 220 mm;  40 slices; voxel size
3 mm  × 3 mm × 3 mm;  no gap; 80◦ ﬂip angle, SENSE 2.0.
2.4. fMRI
The reward anticipation task was presented by a video pro-
jection system onto a white screen using E-prime software
(Psychological Software Tools, USA). Subjects saw the screen via
a mirror attached to the head coil. Responses were logged via a
response box attached to the computer presenting the stimuli.
Subjects were asked to imagine actually receiving the amounts dis-
played in the task, but did not receive any additional reward apart
from their ﬁnancial compensation for participation. We  chose this
option because playing for points or real money has led to similar
results in reward response (Cole et al., 2012; Peters et al., 2011).
All  subjects performed a modiﬁed version of the monetary
incentive delay task as described in Knutson et al. (2001). In the
task the response to anticipation of gaining or losing money and
a neutral condition was determined. Three graded positive cue
stimuli signaled that, if the subjects responded on the subsequent
target presentation, he would gain a monetary reward (36 trials),
three graded negative stimuli signaled that, if the subject would
not respond to the target presentation, he would loose money
(36 trials). One neutral cue, ﬁnally, signaled no incentive outcome
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18 trials). An indication on the stimulus signaled the size of the
eward or loss (D 0.00, D 0.20, D 1.00 or D 5.00). Stimuli (presented
or 250 ms)  were presented in a pseudorandom order. Each cue was
eplaced by a cross-hair with variable delay during the anticipation
eriod (2000–2500 ms). Thereafter, the target was presented for a
ariable length of time (160–260 ms)  and subjects were instructed
o respond as fast as possible to the target by pressing a button with
heir right index ﬁnger. Responding in time to the target would
esult in monetary gain or avoidance of loss. Next, again with a
ariable delay of 1240–1840 ms  after target presentation, feedback
f the trial result and the accumulated result of all previous trials
as provided for a ﬁxed period of 1750 ms  after which a new cue
as presented
.5.  Analysis
Continuous variables of group characteristics were analyzed
sing unpaired two-tailed Student’s t-tests (log transformed if nec-
ssary) and Mann–Whitney tests for drug history variables. All
emographic and behavioral data was analyzed in SPSS version
8.0 (SPSS Inc, Chicago, IL) and are presented as mean ± standard
eviation unless otherwise indicated.
Behavioral responses to the anticipation of reward task were
nalyzed for percentage correct response and mean response time
ith MANOVA for group and MPH  interaction. MRI scans were ana-
yzed using FSL 5.1 (FMRIB-Software-Library, Functional Magnetic
esonance Imaging of the Brain Center, Dept. of Clinical Neurol-
gy, University of Oxford, Oxford, UK, http://www.fmrib.ox.ac.uk).
on-brain  structures were removed from 3D T1 anatomical scans
sing the Brain Extraction Tool (BET; Smith, 2002). Scans were ana-
yzed using FSL’s fMRI Expert Analysis Tool (FEAT; Beckmann et al.,
003) and Motion Correction using FMRIB’s Linear Image Registra-
ion Tool (MCFLIRT; Jenkinson et al., 2002), BET brain extraction,
patial smoothing set at 5 mm FWHM,  high-pass ﬁlter cut-off at
00 s. Scans were registered to the high resolution structural image
nd to standard MNI  space (MNI152 T1 2 mm brain from the FSL
tlas library).
The  general linear model (GLM) used for ﬁrst-level analysis
as adapted from Knutson et al. (2001), with contrasts set to
eward versus neutral, loss versus neutral, reward versus loss and
arge reward (D 5.00) versus small reward (D 0.20). The obtained
rst-level analysis was entered into a second-level (group effect)
nalysis. Main task effect was determined by examining ﬁrst level
ffects for all scans available, both baseline and post-challenge
cans were used for this analysis. Next a mask of the corpus stri-
tum based on the Harvard–Oxford brain atlas, including putamen,
able 1
emographics for dAMPH users and controls with standard deviation (±) and p-values fo
dAMPH n=8
Age 26.0 (±4.0) 
DART-IQ  104.5 (±3.0) 
Years  of education 15.1 (±3.6) 
dAMPH
Average  dAMPH use (occasions/year) 27.8 (±17.1) 
Duration  of dAMPH use (years) 13.9 (±8.7) 
Usual  dose (g/occasion) 0.8 (±1.2) 
Total  exposure (g) 352.6 (±465.3) 
Time  since last exposure (months) 1.1 (±1.3) 
Other  substances
Average tobacco use (cigarettes/month) 261.0 (±279.8) 
Average  alcohol use (units/month) 103.5 (±146.6) 
Average  cannabis use (joints/year) 410.3(±480.5) 
Average  MDMA  use (pills/year) 3.8(±10.6) 
Average  cocaine use (occasions/year) 5.0(±5.2) 
A, not applicable Dependence 130 (2013) 52– 60
caudate,  nucleus accumbens and globus pallidus, was applied to
the data, to determine ROI speciﬁc activation. Because cocaine also
inﬂuences the DA system and cocaine use was  common in dAMPH
we decided to incorporate cocaine in the analysis. Cocaine use in
the last 12 months was  demeaned and added as a covariate to
the higher-level analysis. In order to keep covariate use as low
as possible in this explorative study we  decided against correct-
ing for age and IQ, seeing as we  do not consider these to have a
signiﬁcant inﬂuence on DAergic function in this relatively young
population.
For illustrative purposes we determined striatal task-activation
for both groups and conditions separately, uncorrected with
p < 0.01. Baseline group differences, in addition to the effect of
the challenge per group were calculated. The interaction effect
of group × drug challenge was  calculated. For these comparisons
(baseline effect, challenge effect and interaction) statistical thresh-
old was set at p = 0.05, Z = 2.3, with cluster-correction to correct
for multiple comparisons. Finally, voxels that showed a signiﬁcant
interaction effect were used to create a mask in order to determine
mean percentage signal change in these voxels.
3. Results
3.1. Sample characteristics
The  dAMPH group used dAMPH for a mean of 13.9 (±8.7) years
on a mean of 27.8 (±17.1) occasions/year and a usual dose of
0.8 (±1.2) g/occasion. The mean cumulative lifetime exposure to
dAMPH was 352.6 (±465.3) g and mean time since the last dose
was 1.1 (±1.3) months. Table 1 shows that the dAMPH group was
slightly older and had a normal but slightly lower pre-morbid IQ
than the control group although years of education did not differ
signiﬁcantly. In addition, dAMPH users had used signiﬁcantly more
tobacco, cannabis and cocaine.
3.2. Behavioral effects of reward anticipation
Hit rate for reward anticipation (i.e., proportion of success-
ful button presses during target presentation) and response
times for hits, did not signiﬁcantly differ between controls and
dAMPH users at baseline (hit rate 56.5 ± 13.6% vs. 54.5 ± 7.4%,
p = 0.71; reaction time 197.4 ± 18.8 ms  vs. 197.6 ± 27.9 ms, p = 0.99)
or with MPH  challenge (60.7 ± 15.0% vs. 59.5 ± 10.1%, p = 0.85;
202.8 ± 17.9 ms  vs. 193.1 ± 26.1 ms,  p = 0.4), nor was  there an inter-
action effect of group × challenge (hit rate p = 0.93; reaction time
p = 0.75).
r t-test (Age, IQ and Years of education) or Mann–Whitney test.
Controls  n=8 p-value
22.0 (±3.0) 0.04
110.4 (±4.2) 0.007
16.4 (±2.9) 0.46
0 0.00
NA NA
NA NA
0 0.00
NA NA
0 0.01
104.5(±83.5) 0.49
19.4(±31.8) 0.02
0 0.32
0.1(±0.4) 0.009
M.L.J. Schouw et al. / Drug and Alcohol Dependence 130 (2013) 52– 60 55
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tig. 1. Activation during anticipation of reward vs. anticipation of the neutral cond
OI  of the corpus striatum in healthy controls at baseline (a), dAMPH users at base
fter challenge with MPH  (d). Activated voxels are uncorrected at p < 0.01.
.3. Analysis of reward anticipation
Anticipation  of reward vs. anticipation of the neutral condi-
ion showed activation in the ventral striatum, thalamus, parietal,
rontal and occipital cortex, brainstem, cerebellum, anterior
ingulate and the insular cortex (see Figure S1 available in Sup-
lementary Material).
When  the two groups and drug conditions were analyzed sep-
rately for anticipation of reward vs. anticipation of the neutral
ondition in the corpus striatum ROI, signiﬁcant activation was
bserved in both groups in either drug condition (without and with
PH; Fig. 1). For the control group, widespread and strong activa-
ion was seen in the corpus striatum before the MPH  challenge.
fter the MPH  challenge this effect became weaker and more focal.
n the dAMPH users, anticipation of reward was  associated with
 weak pattern of striatal activation at baseline that did not seem
o be altered by the MPH  challenge. Locations and maximum Z-
cores for these and the following analysis are reported in Table 2.
tatistical comparison of the two groups at baseline (without MPH)
onﬁrmed that anticipation of reward vs. anticipation of the neutral
ondition induced a signiﬁcantly weaker activation pattern across
he striatum of recreational dAMPH users compared to healthy con-
rols (Fig. 2, panel A). Following the MPH  challenge, anticipation of
eward vs. anticipation of the neutral condition induced a statis-
ically signiﬁcant reduction in striatal activation (Fig. 2, panel B)
nly in control subjects. Signiﬁcant clusters (Table 2) were found
n the left caudate, right putamen and right pallidum. In the dAMPH
roup, no statistically signiﬁcant effect of the MPH  challenge was
ound.
No baseline activation or baseline differences were observed
hen analyzing loss versus neutral, reward versus loss or large
eward versus small reward.
.4.  Interaction of group × challenge in striatum during reward
nticipation
A signiﬁcant group × drug challenge interaction was  found in
he left putamen for the anticipation of reward vs. anticipation of. The different panels show the activations during the anticipation of reward in an
b), healthy controls after challenge with 0.5 mg/kg oral MPH  (c) and dAMPH users
a neutral condition contrast (Fig. 2, panel C). The mean percent-
age signal change as shown for the striatum in Fig. 3 during reward
anticipation conﬁrms the different effects induced by reward antic-
ipation in both groups, and the effect of MPH  there upon: under
activation in the dAMPH users at baseline (without MPH) and
reduced brain activation after the MPH  challenge in the controls.
Moreover, in the dAMPH users, the left putamen became more
strongly activated during anticipation of reward after the MPH
challenge.
No interaction effects for the other contrasts (loss versus neu-
tral, reward versus loss, large reward versus small reward) were
observed.
4. Discussion
We  observed a different striatal response following a mone-
tary incentive delay task in recreational dAMPH users compared
to healthy controls. This task has been found to robustly activate
the nucleus accumbens and the caudate when anticipating reward,
where receiving the actual reward mainly elicits a response in
the medial PFC (Knutson et al., 2001; Haber and Knutson, 2010).
When anticipating reward, dAMPH users showed diminished stri-
atal activation in comparison to control subjects. We  also observed
a statistically different effect of a DA challenge in which MPH
induced a decrease in striatal activation during reward anticipation
in healthy controls, whereas no effect in dAMPH users was  found.
No effects of group or challenge were observed on anticipation of
loss and size of the reward.
4.1.  Group differences on anticipation of reward before MPH
challenge
One  of the explanations for the lower reward anticipation found
in recreational dAMPH users may  be an innate hypofunction of
the DAergic system, which, in turn, may  reﬂect increased sensi-
tivity toward dAMPH (ab)use and or addiction. A leading theory
about addiction states that reduced sensitivity for natural rein-
forcers underlies the development of addiction (also referred to
56 M.L.J. Schouw et al. / Drug and Alcohol Dependence 130 (2013) 52– 60
Table 2
Location of the Z-max cluster, with amount of voxels in the cluster, maximum Z-value, p-value and MNI coordinates for the maximum voxel. Analysis given for healthy
controls (HC) and dAMPH users (dAMPH) both before (pre) and after (post) administration of 35 mg  of MPH.
Region Voxels Zmax p-value Talairach
x y z
Baseline
HC
Left caudate/accumbens 1244 5.37 <000 −6 8 −2
Right  caudate/accumbens 1015 5.64 <000 10 12 0
dAMPH  Empty – – – – –
HC  > dAMPH
Left putamen 470 3.6 <001 −22 2 8
Right  putamen 455 3.43 <001 24 4 12
dAMPH  > HC Empty – – – – –
Post-MPH
HC  Empty – – – – –
dAMPH  Empty – – – – –
HC  > dAMPH 131 4.26 0.026 10 0 12
dAMPH  > HC Empty – – – – –
Interaction
HC  pre > post
Left caudate 221 5.6 0.003 −14 16 6
Right  putamen/pallidum 123 4.89 0.023 28 −10 −2
Right  putamen/caudate 93 4.62 0.049 18 18 −4
dAMPH  pre > post Empty – – – – –
a
A
D
d
l
F
o
a
w
c
RHC  > dAMPH
Left putamen/pallidum 105 4.88 
dAMPH  > HC Empty – 
s the reward deﬁciency hypothesis; Comings and Blum, 2000).
ccording to this theory, the dAMPH group may  have an innate
Aergic hypofunction, which, in turn, has predisposed them to
eveloping a penchant for stimulant use. Indeed, even after pro-
onged abstinence, lower D2 receptor availability in a wide variety
ig. 2. Interaction of group × challenge in the striatum during reward anticipation. Panel
f reward between healthy controls and dAMPH users at baseline. Activated voxels indi
nticipation than dAMPH users corrected for cocaine use (Z > 2.3, p < 0.05, cluster-correc
here  a signiﬁcant decrease in activation during reward anticipation was observed in h
orrected). Recreational dAMPH users did not have a signiﬁcant response to MPH (positiv
OI  where a signiﬁcant interaction of group × challenge was  observed (Z > 2.3, p < 0.05, clu0.036 −18 2 6
– – – –
of  addicted individuals has been reported (for review see Volkow
et al., 2009). In addition, lower D2 receptor availability has been
linked to increased impulsivity measures (Buckholtz et al., 2010),
which in itself has been put forward as a component cause for the
development of addiction (for review see Hommer et al., 2011).
 A: Axial, transverse and sagittal views of the difference in response to anticipation
cate areas in which healthy controls had a signiﬁcantly larger response to reward
ted). Panel B: Activated voxels represent the areas within the corpus striatum ROI
ealthy controls after challenge with 0.5 mg/kg oral MPH  (Z > 2.3, p < 0.05, cluster-
e or negative). Panel C: Activated voxels represent areas within the corpus striatum
ster-corrected).
M.L.J. Schouw et al. / Drug and Alcohol
Fig. 3. Mean percentage signal change in nucleus accumbens, striatum and the area
of signiﬁcant interaction (activation mask) during reward anticipation for controls
and dAMPH users at baseline and after MPH  challenge. Bars represent the percentage
signal  change within the ROI from the Harvard–Oxford brain atlas and voxels that
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ehowed a signiﬁcant interaction effect in the voxel-based analysis (activation mask)
or both healthy controls and dAMPH users at baseline and after challenge with
.5 mg/kg oral MPH. Error bars represent standard deviation.
hus, it is possible that our ﬁndings may  not relate to dAMPH use,
ut rather increased impulsivity due to low D2 receptor availabil-
ty. However, we cannot exclude the possibility that selection bias
r confounding by factors that were not included in the current
tudy are responsible for the observed differences in this explo-
ative study. Only a large-scale prospective study, as we  previously
onducted for MDMA  (de Win  et al., 2008), will be able to show
he causal nature of our ﬁndings, and exclude that pre-existing
ifferences (such as low D2 receptor availability) underlie our
ndings.
Addiction has also long been associated with aberrant reward-
elated responses (for a review see Volkow et al., 2011). It has been
emonstrated that alcoholics show reduced ventral striatum acti-
ation during the anticipation of monetary gain (Wrase et al., 2007)
nd a correlation between this response and impulsivity meas-
res has also been reported (Beck et al., 2009). However, cocaine
ependent were not different from healthy controls in the antici-
ation of reward (Asensio et al., 2010). Therefore addiction alone
annot be held exclusively responsible for the changes in reward-
elated behavior. Although we cannot exclude that the participants
n our study were addicted, they clearly stated that they were
ecreational dAMPH users and not diagnosed with addiction or sub-
tance abuse in the past. Moreover, they used dAMPH “only” 28
imes per year, which is about once every two weeks and this can
ardly be called addictive use of dAMPH with loss of control. There-
ore, it is unlikely that addiction-related changes in the mesolimbic
A pathway involved in drug-reward are the predominant mech-
nism underlying our results.
Another  explanation for the reduced sensitivity for reward in
he recreational dAMPH users is that this is caused by neuro-
oxic changes induced by chronic dAMPH use. This interpretation
s based on a large body of preclinical studies, such as that from
icaurte et al. (2005) who observed a reduction in the number of
oth DAT and vesicular monoamine transporter (VMAT) in non-
uman primates treated with a dAMPH in a regimen similar to
he one used in the treatment of patients with ADHD (Ricaurte
t al., 2005). In addition, PET studies in amphetamine treated
ervet monkeys have shown reductions in striatal [18F]ﬂuoro-l-
opa uptake (Melega et al., 1996, 1997) and reductions in DAT
ave been observed in combined dAMPH and MDMA  users using
123I]-CIT SPECT (Reneman et al., 2002). Furthermore, studies on
he striatal DAergic system in rats have shown that chronic dAMPH
xposure results in neurotoxicity characterized by decreases in DA
evels and DAT densities, swollen nerve terminals and degener-
ted axons (Ricaurte et al., 1984). Given the large body of evidence
irectly documenting the DAergic neurotoxic potential of dAMPH
n rodents and nonhuman primates, and because reward functions
re strongly connected to the DA system, our data provide further
vidence that recreational use of dAMPH is associated with DAergic Dependence 130 (2013) 52– 60 57
dysfunction,  as evidenced by a reduced activation during reward
anticipation.
4.2. MPH challenge effect
Our ﬁndings of diminished brain activation of the ventral stri-
atum of healthy controls following an acute challenge with MPH
are in line with the literature. Knutson et al. (2004) investigated the
effects of 0.25 mg/kg oral dAMPH in healthy volunteers, using a sim-
ilar monetary incentive delay task to the one used here, and found
that dAMPH blunted the response in the ventral striatum during
reward anticipation. However, since dAMPH not only blocks the
DAT (similar to MPH), but also enhances DA release, it is expected
that higher synaptic DA concentrations were obtained in the study
by Knutson than in the current study. It is thought that the mag-
nitude of phasic DA release in the ventral striatum is reduced by a
challenge with a DA agent such as dAMPH or MPH  during antici-
pation of reward (Knutson et al., 2004), thereby diminishing brain
activation. In dAMPH users we  did not observe such a response,
providing further evidence for striatal dysfunction.
This dysfunction may  also be linked to the phenomenon of drug
tolerance. It has been shown that repeated dosing with dAMPH
leads to a greater behavioral response and can cause an increased
DA release in response to a subsequent challenge which can still
be observed one year later (Boileau et al., 2006; Strakowski et al.,
1996). After continued exposure this increased sensitivity disap-
pears and DA release is smaller in response to a similar dose (Jacobs
et al., 1981; Segal and Kuczenski, 1997). One theory states that
this is due to depleted DA stores or alterations in D2 auto-receptor
function (Kuczenski and Segal, 1997). Using D1 or D2 receptor spe-
ciﬁc agonists or antagonists, phMRI studies in rats, combined with
microdialysis have demonstrated that speciﬁc receptor types are
responsible for different aspects of the hemodynamic response to
a DAergic challenge (Chen et al., 2005, 2010; Dixon et al., 2005).
Where the D1 receptor is only present post-synaptically, the D2
receptor is expressed both pre- and post-synaptically and can
inhibit DA release when located on the pre-synaptic neuron (for
review see Missale et al., 1998). A lower level of D2 expression may
lead to a larger relative percentage of D2 occupation by DA follow-
ing a challenge, leading to a blunted hemodynamic response to the
MPH  administration. This mechanism could be responsible for the
blunted response we observed in individuals that used dAMPH on a
regular basis. In line with this, a reduction in D2 receptors has been
found in non-human primates following chronic dAMPH treatment
(Ginovart et al., 1999). Reduced levels of D2 expression may  there-
fore also explain the blunted hemodynamic response observed and
this may  also be a result of the dAMPH use in our group of dAMPH
users. However, a lower D2 expression (linked to increased impuls-
ivity as stated above) could also have been pre-existent to the
dAMPH use and causative for the start of psychostimulant use in
these subjects.
Another explanation for the blunted hemodynamic response
could lie in the reduction in DAT availability noted previously in
preclinical studies and possibly other parts of the DAergic system
(Ricaurte et al., 2005). Interference with MPH’s ability to bind to
DAT has been shown to fail to produce conditioned place prefer-
ence behavior, which is related to reward processing (Tilley and Gu,
2008).
In line with this, recent studies revealed a lower response in the
ventral striatum during anticipation of monetary rewards in ado-
lescents (Scheres et al., 2008) and adults with ADHD (Plichta et al.,
2009). This is of interest to the current study, because ADHD has also
been associated with DAergic dysfunction and alterations in DAT
availability have been observed previously (Spencer et al., 2005;
Strohle et al., 2008). In fact, MPH  treatment at (pre)adolescence
seems to reduce this risk of developing addictive disorders in
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ndividuals with ADHD (Katusic et al., 2005; Wilens, 2004). Several
nimal and behavioral studies have suggested that the increased
isk for developing addiction may  be due to aberrant reward sen-
itivity in individuals diagnosed with ADHD (Luman et al., 2005;
hiels et al., 2009; Wilkison et al., 1995). It would be interesting to
se phMRI with a DAergic challenge to investigate reward sensitiv-
ty individuals suffering from ADHD as well as evaluating effects of
reatment on the hemodynamic response proﬁle.
.3. Limitations
First, the number of participants in this study was  rather small.
he study was designed as explorative involving a limited number
f subjects, because predominant dAMPH users are very difﬁcult to
nd in the Amsterdam region. However, even with this relatively
mall sample size, effects were considerable and signiﬁcant even
hen using strict statistical thresholding.
Second, it cannot be excluded that the observed DAergic dys-
unction is due to other drugs than dAMPH since AMPH users had
ore experience with tobacco, cannabis and cocaine then controls.
owever, other than cocaine, none of these drugs is known to affect
he integrity of the DAergic system. For that reason we performed
ost hoc analyses adjusting for cocaine use. It is therefore unlikely
hat the ﬁndings of the present study are caused by substances
ther than dAMPH. Furthermore, because subjects had to abstain
or 2 weeks from psychoactive drugs, it is unlikely that the present
ndings of DAergic dysfunction are due to the acute pharmacologi-
al effects of dAMPH or other drugs (other than MPH administered
uring the study). Urine screening was performed to detect con-
ealed recent dAMPH use. Other than self-report, we were not able
o ensure abstention from dAMPH in the two weeks before the scan-
ing sessions. However, a survey in The Netherlands investigated
he validity of the drug-history questionnaire that was used in this
tudy. It was found that in 93% of the cases (n = 594) the reported
rug use was in agreement with the drug-urine test (Addiction
esearch Institute, 1998). In future studies, hair sample analysis
ould be a useful way to ascertain previous use of dAMPH.
Age  and IQ also differed between the groups. Therefore,
dditional or supplementary statistical analyses to the analyses
nvolving the primary objective of the study were conducted with
ge and IQ as covariates (Figures S2 and S3 in Supplementary Mate-
ial). However, these covariates did not substantially change our
ndings: we again observed larger activation in healthy controls
hen compared to dAMPH users at baseline, along with an inter-
ction effect of the MPH  challenge. This observation strengthens
he hypothesis that our ﬁndings are related to stimulant use and
ot to mismatched characteristics.
Thirdly, because we did not include a placebo challenge we can-
ot completely rule out the possibility that differences between the
roups in expectation of drug effect may  have affected our results.
owever, none of the groups had previous experience with MPH
nd did not know (exactly) what to expect. Moreover, a previous
tudy only found a small expectancy effect on brain hemodynamics
ith i.v. administration of MPH, whereas in the current study MPH
as given orally (probably resulting in an even smaller expectancy
ffect; Volkow et al., 2006). In addition, this expectancy effect dur-
ng i.v. MPH  administration was observed only on resting state
RI and not on task-related brain hemodynamics. These observa-
ions suggest that in the current study drug expectancy may  have
ffected the results only minimally, if at all.
Fourth, we did not use an actual monetary reward. However, our
esults on whole brain activation to the anticipation of gain are very
imilar to earlier results obtained with this task. This task itself has
een applied with modiﬁed rewards in previous studies as well
points with which subject could purchase snacks (Peters et al.,
011), monetary reward with a maximum thresholds or globally Dependence 130 (2013) 52– 60
linking  performance to size of compensation for study participa-
tion (Jia et al., 2011)). Hahn et al. (2011) and Stoy et al. (2011) do
not specify whether or not actual money was used. Interestingly,
similar results were obtained in all these modiﬁed reward studies.
Because the Knutson group who  designed our task found robust
activation of reward related systems in the anticipation of interac-
tive game playing, involving no other reward than playing the game
itself (Cole et al., 2012), we feel that our results are trustworthy even
with only the ﬁctitious winning of money.
5. Conclusion
To our knowledge, this is the ﬁrst study investigating DAer-
gic dysfunction in recreational users of dAMPH using a monetary
incentive delay task with fMRI. We  not only observed a blunted
brain activation response during anticipation of reward in dAMPH
users, but we also following a DAergic challenge with MPH. These
ﬁndings provide further evidence for frontostriatal DA dysfunction
in recreational dAMPH users and in our opinion are consistent with
preclinical data suggesting neurotoxic effects of chronic dAMPH
use. It should be noted, however, that no performance deﬁcits were
present in this relatively small study. Our ﬁndings should, therefore,
be replicated in a larger sample. When replicated, our ﬁndings could
also be used to further investigate the effects of chronic low dose
dAMPH in a clinical setting, for example in the treatment of ADHD.
Role of funding source
This  work was funded by a Research Fellowship from the Aca-
demic Medical Center, Amsterdam the Netherlands, awarded to L.
Reneman; the funding organization had no further role in study
design; in the collection, analysis and interpretation of data; in the
writing of the report; and in the decision to submit the paper for
publication.
Contributors
Liesbeth Reneman designed the study and wrote the protocol.
Marieke Schouw collected the data, performed the fMRI analysis
and wrote the ﬁrst draft of the article. Michiel de Ruiter advised on
the fMRI analysis. Anne Marije Kaag helped with fMRI analysis and
processed all demographic and behavioral data. Wim  van de Brink
and Ramon Lindauer provided valuable input on data handling and
the writing of the manuscript. All authors contributed to and have
approved the ﬁnal manuscript.
Conﬂict  of interest
The  authors report no conﬂict of interest.
Acknowledgements
The authors would like to sincerely thank Brian Knutson for
providing his fMRI task for our use. In addition we would like to
thank all participants of our study and the funding organizations
for making the entire process possible.
Appendix A. Supplementary dataSupplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.drugalcdep.
2012.10.010.
lcohol
R
A
A
B
B
B
B
B
C
C
C
C
d
D
E
G
H
H
H
H
J
J
J
K
K
K
K
LM.L.J. Schouw et al. / Drug and A
eferences
ddiction Research Institute (US), 1998. Ecstasy and the Dutch rave scene: a socio-
epidemiological study on the nature and extent of, and the risks involved in using
ecstasy and other party drugs at dance events. University of Utrecht, Utrecht.
sensio, S., Romero, M.J., Romero, F.J., Wong, C., Alia-Klein, N., Tomasi, D., Wang,
G.J.,  Telang, F., Volkow, N.D., Goldstein, R.Z., 2010. Striatal dopamine D2 receptor
availability  predicts the thalamic and medial prefrontal responses to reward in
cocaine abusers three years later. Synapse 64, 397–402.
eck,  A., Schlagenhauf, F., Wustenberg, T., Hein, J., Kienast, T., Kahnt, T., Schmack, K.,
Hagele, C., Knutson, B., Heinz, A., Wrase, J., 2009. Ventral striatal activation dur-
ing  reward anticipation correlates with impulsivity in alcoholics. Biol. Psychiatry
66,  734–742.
eckmann, C.F., Jenkinson, M.,  Smith, S.M., 2003. General multilevel linear modeling
for group analysis in fMRI. Neuroimage 20, 1052–1063.
oileau, I., Dagher, A., Leyton, M.,  Gunn, R.N., Baker, G.B., Diksic, M.,
Benkelfat,  C., 2006. Modeling sensitization to stimulants in humans: an
[11C]raclopride/positron emission tomography study in healthy men. Arch. Gen.
Psychiatry 63, 1386–1395.
uckholtz,  J.W., Treadway, M.T., Cowan, R.L., Woodward, N.D., Li, R., Ansari, M.S.,
Baldwin, R.M., Schwartzman, A.N., Shelby, E.S., Smith, C.E., Kessler, R.M., Zald,
D.H.,  2010. Dopaminergic network differences in human impulsivity. Science
329,  532.
ush, G., Spencer, T.J., Holmes, J., Shin, L.M., Valera, E.M., Seidman, L.J., Makris, N., Sur-
man, C., Aleardi, M.,  Mick, E., Biederman, J., 2008. Functional magnetic resonance
imaging  of methylphenidate and placebo in attention-deﬁcit/hyperactivity dis-
order during the multi-source interference task. Arch. Gen. Psychiatry 65,
102–114.
hen,  Y.I., Choi, J.K., Jenkins, B.G., 2005. Mapping interactions between dopamine
and  adenosine A2a receptors using pharmacologic MRI. Synapse 55, 80–88.
hen, Y.I., Choi, J.K., Xu, H., Ren, J., Andersen, S.L., Jenkins, B.G., 2010. Pharmacologic
neuroimaging  of the ontogeny of dopamine receptor function. Dev. Neurosci.
32,  125–138.
ole, S.W., Yoo, D.J., Knutson, B., 2012. Interactivity and reward-related neural acti-
vation during a serious videogame. PLoS One 7, e33909.
omings, D.E., Blum, K., 2000. Reward deﬁciency syndrome: genetic aspects of
behavioral disorders. Prog. Brain Res. 126, 325–341.
e  Win, M.M.,  Jager, G., Booij, J., Reneman, L., Schilt, T., Lavini, C., Olabarriaga, S.D., Den
Heeten, G.J., van den Brink, W.,  2008. Sustained effects of ecstasy on the human
brain:  a prospective neuroimaging study in novel users. Brain 131, 2936–2945.
ixon, A.L., Prior, M.,  Morris, P.M., Shah, Y.B., Joseph, M.H., Young, A.M., 2005.
Dopamine  antagonist modulation of amphetamine response as detected using
pharmacological MRI. Neuropharmacology 48, 236–245.
rsche,  K.D., Fletcher, P.C., Lewis, S.J., Clark, L., Stocks-Gee, G., London, M.,  Deakin,
J.B., Robbins, T.W., Sahakian, B.J., 2005. Abnormal frontal activations related to
decision-making in current and former amphetamine and opiate dependent
individuals.  Psychopharmacology (Berl.) 180, 612–623.
inovart, N., Farde, L., Halldin, C., Swahn, C.G., 1999. Changes in striatal D2-receptor
density following chronic treatment with amphetamine as assessed with PET in
nonhuman primates. Synapse 31, 154–162.
aber, S.N., Knutson, B., 2010. The reward circuit: linking primate anatomy and
human imaging. Neuropsychopharmacology 35, 4–26.
ahn,  T., Heinzel, S., Dresler, T., Plichta, M.M.,  Renner, T.J., Markulin, F., Jakob, P.M.,
Lesch, K.P., Fallgatter, A.J., 2011. Association between reward-related activation
in  the ventral striatum and trait reward sensitivity is moderated by dopamine
transporter  genotype. Hum. Brain Mapp. 32, 1557–1565.
ommer, D.W., Bjork, J.M., Gilman, J.M., 2011. Imaging brain response to reward in
addictive disorders. Ann. N.Y. Acad. Sci. 1216, 50–61.
oney, G., Bullmore, E., 2004. Human pharmacological MRI. Trends Pharmacol. Sci.
25, 366–374.
acobs, B.L., Heym, J., Trulson, M.E., 1981. Cats develop tolerance to d-amphetamine’s
effects  upon locomotion and stereotyped behaviors. Eur. J. Pharmacol. 69,
353–356.
enkinson,  M.,  Bannister, P., Brady, M.,  Smith, S., 2002. Improved optimization for the
robust and accurate linear registration and motion correction of brain images.
Neuroimage  17, 825–841.
ia,  Z., Worhunsky, P.D., Carroll, K.M., Rounsaville, B.J., Stevens, M.C., Pearlson, G.D.,
Potenza, M.N., 2011. An initial study of neural responses to monetary incentives
as  related to treatment outcome in cocaine dependence. Biol. Psychiatry 70,
553–560.
atusic,  S.K., Barbaresi, W.J., Colligan, R.C., Weaver, A.L., Leibson, C.L., Jacobsen, S.J.,
2005. Psychostimulant treatment and risk for substance abuse among young
adults with a history of attention-deﬁcit/hyperactivity disorder: a population-
based,  birth cohort study. J. Child Adolesc. Psychopharmacol. 15, 764–776.
nutson, B., Adams, C.M., Fong, G.W., Hommer, D., 2001. Anticipation of increasing
monetary  reward selectively recruits nucleus accumbens. J. Neurosci. 21, RC159.
nutson,  B., Bjork, J.M., Fong, G.W., Hommer, D., Mattay, V.S., Weinberger, D.R., 2004.
Amphetamine modulates human incentive processing. Neuron 43, 261–269.
uczenski, R., Segal, D.S., 1997. An escalating dose/multiple high-dose binge pattern
of amphetamine administration results in differential changes in the extracel-
lular  dopamine response proﬁles in caudate-putamen and nucleus accumbens.
J.  Neurosci. 17, 4441–4447.
iddle,  E.B., Hollis, C., Batty, M.J., Groom, M.J., Totman, J.J., Liotti, M.,  Scerif, G., Liddle,
P.F., 2011. Task-related default mode network modulation and inhibitory control
in  ADHD: effects of motivation and methylphenidate. J. Child Psychol. Psychiatry
52,  761–771. Dependence 130 (2013) 52– 60 59
Luman, M.,  Oosterlaan, J., Sergeant, J.A., 2005. The impact of reinforcement contin-
gencies  on AD/HD: a review and theoretical appraisal. Clin. Psychol. Rev. 25,
183–213.
Melega,  W.P., Quintana, J., Raleigh, M.J., Stout, D.B., Yu, D.C., Lin, K.P., Huang, S.C.,
Phelps,  M.E., 1996. 6-[18F]ﬂuoro-l-DOPA-PET studies show partial reversibil-
ity  of long-term effects of chronic amphetamine in monkeys. Synapse 22,
63–69.
Melega,  W.P., Raleigh, M.J., Stout, D.B., Lacan, G., Huang, S.C., Phelps, M.E.,
1997.  Recovery of striatal dopamine function after acute amphetamine- and
methamphetamine-induced neurotoxicity in the vervet monkey. Brain Res. 766,
113–120.
Missale, C., Nash, S.R., Robinson, S.W., Jaber, M.,  Caron, M.G., 1998. Dopamine recep-
tors: from structure to function. Physiol. Rev. 78, 189–225.
Ornstein, T.J., Iddon, J.L., Baldacchino, A.M., Sahakian, B.J., London, M.,  Everitt, B.J.,
Robbins, T.W., 2000. Proﬁles of cognitive dysfunction in chronic amphetamine
and  heroin abusers. Neuropsychopharmacology 23, 113–126.
Peters,  J., Bromberg, U., Schneider, S., Brassen, S., Menz, M.,  Banaschewski, T., Conrod,
P.J., Flor, H., Gallinat, J., Garavan, H., Heinz, A., Itterman, B., Lathrop, M.,  Mar-
tinot,  J.L., Paus, T., Poline, J.B., Robbins, T.W., Rietschel, M., Smolka, M., Strohle,
A.,  Struve, M., Loth, E., Schumann, G., Buchel, C., 2011. Lower ventral striatal
activation  during reward anticipation in adolescent smokers. Am.  J. Psychiatry
168,  540–549.
Plichta, M.M.,  Vasic, N., Wolf, R.C., Lesch, K.P., Brummer, D., Jacob, C.,
Fallgatter,  A.J., Gron, G., 2009. Neural hyporesponsiveness and hyper-
responsiveness during immediate and delayed reward processing
in  adult attention-deﬁcit/hyperactivity disorder. Biol. Psychiatry 65,
7–14.
Rapeli,  P., Kivisaari, R., Kahkonen, S., Puuskari, V., Autti, T., Kalska, H.,  2005. Do indi-
viduals with former amphetamine dependence have cognitive deﬁcits? Nord. J.
Psychiatry 59, 293–297.
Reneman,  L., Booij, J., Lavalaye, J., de Bruin, K., Reitsma, J.B., Gunning, B., Den Heeten,
G.J.,  van den Brink, W.,  2002. Use of amphetamine by recreational users of ecstasy
(MDMA) is associated with reduced striatal dopamine transporter densities:
a  [123I]beta-CIT SPECT study—preliminary report. Psychopharmacology (Berl.)
159,  335–340.
Ricaurte, G.A., Mechan, A.O., Yuan, J., Hatzidimitriou, G., Xie, T., Mayne, A.H., McCann,
U.D., 2005. Amphetamine treatment similar to that used in the treatment of adult
attention-deﬁcit/hyperactivity disorder damages dopaminergic nerve endings
in the striatum of adult nonhuman primates. J. Pharmacol. Exp. Ther. 315,
91–98.
Ricaurte,  G.A., Seiden, L.S., Schuster, C.R., 1984. Further evidence that amphetamines
produce  long-lasting dopamine neurochemical deﬁcits by destroying dopamine
nerve  ﬁbers. Brain Res. 303, 359–364.
Rubia, K., Halari, R., Cubillo, A., Mohammad, A.M., Brammer, M.,  Taylor, E., 2009.
Methylphenidate  normalises activation and functional connectivity deﬁcits in
attention and motivation networks in medication-naive children with ADHD
during  a rewarded continuous performance task. Neuropharmacology 57,
640–652.
Scheres,  A., Lee, A., Sumiya, M., 2008. Temporal reward discounting and ADHD: task
and symptom speciﬁc effects. J. Neural Transm. 115, 221–226.
Schlosser,  R.G., Nenadic, I., Wagner, G., Zysset, S., Koch, K., Sauer, H., 2009.
Dopaminergic  modulation of brain systems subserving decision making under
uncertainty:  a study with fMRI and methylphenidate challenge. Synapse 63,
429–442.
Schultz,  W.,  2002. Getting formal with dopamine and reward. Neuron 36, 241–263.
Segal, D.S., Kuczenski, R., 1997. Behavioral alterations induced by an esca-
lating  dose-binge pattern of cocaine administration. Behav. Brain Res. 88,
251–260.
Shafritz,  K.M., Marchione, K.E., Gore, J.C., Shaywitz, S.E., Shaywitz, B.A., 2004. The
effects of methylphenidate on neural systems of attention in attention deﬁcit
hyperactivity  disorder. Am.  J. Psychiatry 161, 1990–1997.
Shiels, K., Hawk Jr., L.W., Reynolds, B., Mazzullo, R.J., Rhodes, J.D., Pelham Jr., W.E.,
Waxmonsky, J.G., Gangloff, B.P., 2009. Effects of methylphenidate on discount-
ing  of delayed rewards in attention deﬁcit/hyperactivity disorder. Exp. Clin.
Psychopharmacol.  17, 291–301.
Smith, S.M., 2002. Fast robust automated brain extraction. Hum. Brain Mapp. 17,
143–155.
Spencer, T.J., Biederman, J., Madras, B.K., Faraone, S.V., Dougherty, D.D., Bonab,
A.A., Fischman, A.J., 2005. In vivo neuroreceptor imaging in attention-
deﬁcit/hyperactivity disorder: a focus on the dopamine transporter. Biol.
Psychiatry  57, 1293–1300.
Stoy,  M.,  Schlagenhauf, F., Schlochtermeier, L., Wrase, J., Knutson, B., Lehmkuhl, U.,
Huss, M., Heinz, A., Strohle, A., 2011. Reward processing in male adults with
childhood  ADHD—a comparison between drug-naive and methylphenidate-
treated subjects. Psychopharmacology (Berl.) 215, 467–481.
Strakowski, S.M., Sax, K.W., Setters, M.J., Keck Jr., P.E., 1996. Enhanced response
to  repeated d-amphetamine challenge: evidence for behavioral sensitization in
humans. Biol. Psychiatry 40, 872–880.
Strohle, A., Stoy, M.,  Wrase, J., Schwarzer, S., Schlagenhauf, F., Huss, M.,
Hein,  J., Nedderhut, A., Neumann, B., Gregor, A., Juckel, G., Knutson, B.,
Lehmkuhl,  U., Bauer, M.,  Heinz, A., 2008. Reward anticipation and outcomes
in  adult males with attention-deﬁcit/hyperactivity disorder. Neuroimage 39,
966–972.
Swanson, J.M., Volkow, N.D., 2003. Serum and brain concentrations of
methylphenidate: implications for use and abuse. Neurosci. Biobehav.
Rev.  27, 615–621.
6 lcohol
T
V
V
V
V
V0 M.L.J. Schouw et al. / Drug and A
illey, M.R., Gu, H.H., 2008. The effects of methylphenidate on knockin mice with a
methylphenidate-resistant dopamine transporter. J. Pharmacol. Exp. Ther. 327,
554–560.
aidya, C.J., Austin, G., Kirkorian, G., Ridlehuber, H.W., Desmond, J.E., Glover, G.H.,
Gabrieli, J.D., 1998. Selective effects of methylphenidate in attention deﬁcit
hyperactivity  disorder: a functional magnetic resonance study. Proc. Natl. Acad.
Sci. U.S.A. 95, 14494–14499.
an  den Heuvel, D.M., Pasterkamp, R.J., 2008. Getting connected in the dopamine
system.  Prog. Neurobiol. 85, 75–93.
olkow, N.D., Wang, G.J., Fowler, J.S., Tomasi, D., Telang, F., 2011. Addiction: beyond
dopamine reward circuitry. Proc. Natl. Acad. Sci. U.S.A. 108, 15037–15042.
olkow,  N.D., Wang, G.J., Kollins, S.H., Wigal, T.L., Newcorn, J.H., Telang, F., Fowler,
J.S.,  Zhu, W.,  Logan, J., Ma,  Y., Pradhan, K., Wong, C., Swanson, J.M., 2009. Eval-
uating  dopamine reward pathway in ADHD: clinical implications. JAMA 302,
1084–1091.
olkow,  N.D., Wang, G.J., Ma,  Y., Fowler, J.S., Wong, C., Jayne, M., Telang, F., Swan-
son,  J.M., 2006. Effects of expectation on the brain metabolic responses to
methylphenidate  and to its placebo in non-drug abusing subjects. Neuroimage
32,  1782–1792. Dependence 130 (2013) 52– 60
Wilens, T.E., 2004. Attention-deﬁcit/hyperactivity disorder and the substance use
disorders: the nature of the relationship, subtypes at risk, and treatment issues.
Psychiatr.  Clin. North Am. 27, 283–301.
Wilens, T.E., Adler, L.A., Adams, J., Sgambati, S., Rotrosen, J., Sawtelle, R., Utzinger,
L.,  Fusillo, S., 2008. Misuse and diversion of stimulants prescribed for ADHD: a
systematic review of the literature. J. Am. Acad. Child Adolesc. Psychiatry 47,
21–31.
Wilkison,  P.C., Kircher, J.C., McMahon, W.M.,  Sloane, H.N., 1995. Effects of
methylphenidate  on reward strength in boys with attention-deﬁcit
hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 34,
897–901.
Willson,  M.C., Wilman, A.H., Bell, E.C., Asghar, S.J., Silverstone, P.H., 2004. Dextroam-
phetamine  causes a change in regional brain activity in vivo during cognitive
tasks:  a functional magnetic resonance imaging study of blood oxygen level-
dependent  response. Biol. Psychiatry 56, 284–291.
Wrase, J., Schlagenhauf, F., Kienast, T., Wustenberg, T., Bermpohl, F., Kahnt, T., Beck,
A., Strohle, A., Juckel, G., Knutson, B., Heinz, A., 2007. Dysfunction of reward
processing  correlates with alcohol craving in detoxiﬁed alcoholics. Neuroimage
35,  787–794.
